Adalimumab and juvenile arthritis Archives

Abstract Number: 1678 • ACR/ARHP Annual Meeting 2012
Safety and Efficacy of Adalimumab in Children with Active Polyarticular Juvenile Idiopathic Arthritis Aged 2 to <4 Years or ≥4 Years Weighing <15 Kg
Daniel J. Kingsbury¹, Pierre Quartier², Gina Patel³, Vipin Arora⁴, Hartmut Kupper⁵ and Neelufar Mozaffarian³, ¹Randall Children's Hospital at Legacy Emanuel, Portland, OR, ²Unite d'Immuno-Hematologie et Rhumatologie Pediatriques, Paris, France, ³Abbott, Abbott Park, IL, ⁴Health Outcomes Research, Abbott, Abbott Park, IL, ⁵Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany
Background/Purpose: Adalimumab (ADA) is approved for use in moderate to severe JIA in patients (pts) ≥4 yrs old in the US, EU,and Japan. ADA has…
Abstract Number: 1148 • ACR/ARHP Annual Meeting 2012
Adalimumab – Effective Control under Refractory JIA Associated Uveitis
Ekaterina Alekseeva¹, Elena Mitenko², Tatyana Bzarova², Saniya Valieva², Kseniya Isayeva², Alexandra Chomakhidze², Evgeniya Chistyakova², Tatyana Sleptsova² and Rina Denisova², ¹PRINTO, Genoa, Italy, ²Rheumatology, Scientific Center of Children's Health, Moscow, Russia
Background/Purpose: Treatment of juvenile idiopathic arthritis (JIA)–associated uveitis is one of the serious problems of paediatric rheumatology. JIA associated uveitis often is refractory to MTX,…
Abstract Number: 764 • ACR/ARHP Annual Meeting 2012
The Impact of Adalimumab On Growth in Patients with Juvenile Idiopathic Arthritis
D. J. Lovell¹, Nicolino Ruperto², Katerina Jarosova³, Dana Nemcova⁴, Veronika Vargova³, Hartmut Michels³, Elizabeth Chalom⁵, Norman Ilowite⁵, Carine Wouters⁶, Hermine Brunner⁷, Karolyn Kracht⁸, Hartmut Kupper⁹, Edward Giannini⁵, Alberto Martini¹⁰ and Neelufar Mozaffarian¹¹, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genova, Italy, ³PRINTO, Gaslini Institute, Genova, Italy, ⁴Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ⁵PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁶PRINTO, Genoa, Italy, ⁷PRCSG, Cincinnati Children’s Hospital Medical Center, Genova, Italy, ⁸Abbott, Abbott, Abbott Park, IL, ⁹Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ¹⁰Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ¹¹Abbott, Abbott Park, IL
Background/Purpose: Children with juvenile idiopathic arthritis (JIA) often exhibit growth impairments. Treatment with adalimumab (ADA) has been shown to be safe and effective in JIA…

Abstracts tagged "Adalimumab and juvenile arthritis"

Safety and Efficacy of Adalimumab in Children with Active Polyarticular Juvenile Idiopathic Arthritis Aged 2 to <4 Years or ≥4 Years Weighing <15 Kg

Adalimumab – Effective Control under Refractory JIA Associated Uveitis

The Impact of Adalimumab On Growth in Patients with Juvenile Idiopathic Arthritis